Overview

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-30

Target enrollment:

Participant gender:

Summary

This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

HMPL-013